Parameter
Died (n=77)
Survived (n=109)
p
Age (years) 71.1±11 63.1±11.6 0.0001
Male 70 (90.9%) 88 (80.7%) 0.063
ICD 25 (32.4%) 54 (49.5%) 0.024
CRTD 52 (67.5%) 55 (50.4%) 0.024
Ischemic Cardiomyopathy 54 (70.1%) 61 (55.9%) 0.065
Hypertension 56 (72.7%) 74 (67.8%) 0.5
Diabetes mellitus 28 (36.3%) 51 (46.7%) 0.17
Renal dysfunction 34 (44.2%) 32 (29.3%) 0.043
VA during F/U 31 (40.2%) 21 (19.2%) 0.0028
Number of guideline-based medications 2.13±0.75 2.41±0.74 0.007
BB treatment 61 (79.2%) 94 (86.2%) 0.23
BB dose (% target) 29.3%±24% 34.3±27% 0.243
BB > 25% target dose 26 (33.8%) 42 (38.5%) 0.506
AngA treatment 62 (80%) 100 (91.7%) 0.028
AngA dose (% target) 37.6±31% 39.3±28% 0.389
AngA > 25% target dose 37 (48.1%) 53 (48.6%) 0.94
MRA treatment 41 (53.2%) 69 (63.4%) 0.17
MRA dose (% target) 28.2±30% 32.8±29% 0.169
MRA > 25% target dose 30 (39%) 58 (53.2%) 0.055
AAD rate 31 (40.2%) 50 (45.8%) 0.45
BB+AngA+MRA treatment 26 (33.7%) 60 (55%) 0.0047
Follow up period (median[IQR], days) 1398 [567,2361] 1400 [805,2434] 0.27